NCT05268666View on ClinicalTrials.gov

A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

April 8, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

August 31, 2025

Conditions
Locally Advanced Solid TumorMetastatic Solid Tumor
Interventions
DRUG

JBI-802

LSD1/HDAC6 inhibitor

Trial Locations (4)

22031

COMPLETED

NEXT Virginia, LLC, Fairfax

37203

COMPLETED

Tennessee Oncology, PLLC, Nashville

45219

RECRUITING

The Christ Hospital, Cincinnati

82018

COMPLETED

Sarah Cannon Research Institute at HealthOne, Denver

Sponsors
All Listed Sponsors
lead

Jubilant Therapeutics Inc.

INDUSTRY